Ramucirumab

CAS No.: 947687-13-0

Chemical Name:: Ramucirumab

Synonyms: Cyramza;LY3009806;IMC-1121B;Ramucirumab;Ramucirumab (anti-VEGFR2);Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor

CBNumber:: CB72738188

Molecular Formula:

Molecular Weight:: 0

MOL File:: Mol file

Modify Date:: 2024/7/2 8:55:16

Request For Quotation

Ramucirumab Properties

storage temp.	Store at -20°C
solubility	Soluble in DMSO
form	Liquid
color	Colorless to light yellow

Ramucirumab Preparation Products And Raw materials

Raw materials

Preparation Products

Ramucirumab Suppliers

Global( 73)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
Homme Pharma	08048250259Ext 923	Mumbai, India	4	58	Inquiry
Hubei Ipure Biology Co., Ltd	+8613367258412	China	10326	58	Inquiry
Shanghai Minbiotech Co., Ltd.	+8617315815539	CHINA	129	58	Inquiry
AFINE CHEMICALS LIMITED	+86-0571-85134551	China	15395	58	Inquiry
Baoji Guokang Healthchem co.,ltd	+8615604608665 15604608665	CHINA	9427	58	Inquiry
BOC Sciences	16314854226; +16314854226	United States	19743	58	Inquiry
Nantong HI-FUTURE Biology Co., Ltd.	+undefined18051384581	China	3136	58	Inquiry
TargetMol Chemicals Inc.	+1-781-999-5354	United States	19973	58	Inquiry
Wuhan Topule Biopharmaceutical Co., Ltd	+8618327326525	China	8474	58	Inquiry

Supplier	Advantage
CLEARSYNTH LABS LTD.	58
Homme Pharma	58
Hubei Ipure Biology Co., Ltd	58
Shanghai Minbiotech Co., Ltd.	58
AFINE CHEMICALS LIMITED	58
Baoji Guokang Healthchem co.,ltd	58
BOC Sciences	58
Nantong HI-FUTURE Biology Co., Ltd.	58
TargetMol Chemicals Inc.	58
Wuhan Topule Biopharmaceutical Co., Ltd	58

947687-13-0(Ramucirumab)Related Search:

Adalimumab Ustekinumab Nivolumab Bevacizumab Daratumumab

OMALIZUMAB Lambrolizumab Dulaglutide Infliximab Rituximab

palivizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Atezolizumab Denosumab CETUXIMAB

Evolocumab ipilimumab Eculizumab

chevron_left

1of4

chevron_right

Ramucirumab Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor Cyramza IMC-1121B LY3009806 Ramucirumab (anti-VEGFR2) 947687-13-0